UGT1A1 biomarker and colorectal cancer
What is the UGT1A1 biomarker?
The UGT1A1 gene is present in all the cells in our body. The normal UGT1A1 gene providesinstructions for making a certain enzyme called UDP glucuronosyltransferases, which helps the liver break down medications effectively.
What happens if I have the UGT1A1 biomarker?
If you have a mutation in the UGT1A1 gene, your body may not be able to process certain chemotherapy drugs.
Patients with this rare mutation have symptoms such as impaired liver function, low white cell counts, and severe diarrhea.
Your doctor will monitor you closely during your chemotherapy treatment to watch for any adverse reactions.
Who should have UGT1A1 testing?
UGT1A1 mutation testing is not routinely performed.
Patients are often tested if they have experienced severe toxicity during treatment with FOLFIRI, FOLFIRINOX, or irinotecan.
Other biomarkers
SidednessTop resources
FDA approves Tecentriq for some people with stage III colon cancer
The FDA has approved Tecentriq (atezolizumab), given with chemotherapy after surgery, for people with stage III colon cancer whose tumors are mismatch repair deficient (dMMR). It’s the first immunotherapy approved for this use.
Alliance Breaks Down New ACS Screening Guidelines
The Colorectal Cancer Alliance is urging Americans to prioritize colorectal cancer screening, as the American Cancer Society (ACS) released updated guidelines today.
A blood test that sees what scans can't
For many cancer patients, the end of active treatment brings a new kind of dread. Scans every few months and anxious waits for results. A blood test is changing that experience for a growing number of patients.